Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-3.19% $1.365
America/New_York / 26 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 66.40 mill |
EPS: | -1.110 |
P/E: | -1.230 |
Earnings Date: | May 07, 2024 |
SharesOutstanding: | 48.64 mill |
Avg Daily Volume: | 0.261 mill |
RATING 2024-04-26 |
---|
C+ |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Strong Sell | |
Return On Asset: | Strong Sell | |
DE: | Buy | |
P/E: | Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -1.230 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.21x |
Company: PE -1.230 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 1.217 - 1.523 ( +/- 11.17%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-06 | Sandercock Colin | Buy | 175 000 | Stock Option (right to buy) |
2024-03-06 | Suri Anish | Buy | 300 000 | Stock Option (right to buy) |
2024-03-06 | Millar Kerri-ann | Buy | 250 000 | Stock Option (right to buy) |
2024-03-06 | Passeri Daniel R | Buy | 400 000 | Stock Option (right to buy) |
2024-03-06 | Levisetti Matteo | Buy | 260 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
97.97 |
Last 98 transactions |
Buy: 5 498 246 | Sell: 593 660 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $1.365 (-3.19% ) |
Volume | 0.262 mill |
Avg. Vol. | 0.261 mill |
% of Avg. Vol | 100.15 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.